GlassScriptPhysician profile
Suzanne D Kovacs
NPI 1730133646
$14,072.63
in general payments reported to CMS, 2019-2025
69 companies · $2,250 in 2025
The $2,250 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,810 · 2020: $1,587 · 2021: $2,075 · 2022: $1,591 · 2023: $2,335 · 2024: $2,426 · 2025: $2,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,747 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,746.90 |
| Education | $263.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,014.77 | 2019-2025 | |
| Pfizer INC. | $1,511.24 | 2019-2025 | |
| Amgen INC. | $1,240.82 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $910.39 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $671.95 | 2019-2025 | Veozah |
| Lilly USA, LLC | $497.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $491.91 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $436.48 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $427.79 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $379.68 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $366.05 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $341.52 | 2022-2025 | Ingrezza, Ongentys |
| Bayer Healthcare Pharmaceuticals INC. | $289.32 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $261.06 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $260.60 | 2020-2025 | Belsomra, Steglatro, Capvaxive |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $254.75 | 2019-2025 | Zoryve |
| Dexcom, INC. | $244.76 | 2021-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $242.28 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $233.18 | 2019-2022 | |
| Eisai INC. | $197.78 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $195.81 | 2022 | |
| Abbott Laboratories | $182.61 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $182.36 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $168.87 | 2019-2025 | Spravato |
| Daiichi Sankyo INC. | $164.39 | 2019-2025 | Injectafer |
| Esperion Therapeutics, INC. | $148.69 | 2020-2025 | Nexletol |
| Medtronic, INC. | $127.00 | 2023-2025 | Intellis Adaptivestim |
| Biohaven Pharmaceuticals, INC. | $110.60 | 2021 | |
| Supernus Pharmaceuticals, INC. | $109.49 | 2019 | |
| Upsher-Smith Laboratories LLC | $105.46 | 2019-2022 | |
| Exact Sciences Corporation | $104.92 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $70.82 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.27 | 2020-2023 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.20 | 2025 | Caplyta |
| Shield Therapeutics INC | $64.54 | 2024-2025 | |
| Antares Pharma, INC. | $52.96 | 2019-2025 | Xyosted |
| Phathom Pharmaceuticals, INC. | $51.86 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $50.10 | 2020-2021 | |
| Ibsa Pharma INC. | $47.64 | 2021-2023 | Tirosint, Licart |
| Edwards Lifesciences Corporation | $46.51 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Acadia Pharmaceuticals INC | $45.42 | 2019 | |
| Philips North America LLC | $43.97 | 2020 | |
| Verona Pharma, INC. | $38.32 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $38.20 | 2025 | Auvelity, Symbravo |
| E.R. Squibb & Sons, L.L.C. | $37.52 | 2021-2022 | |
| Lundbeck LLC | $36.89 | 2025 | Rexulti |
| Genentech USA, INC. | $32.23 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $30.40 | 2023 | Gvoke Hypopen |
| Bausch Health US, LLC | $28.41 | 2019 | |
| Vifor Pharma, INC. | $25.98 | 2024 | Veltassa |
| Recor Medical INC | $24.82 | 2025 | Paradise Ultrasound Renal Denervation System |
| Inari Medical, INC. | $22.16 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Gilead Sciences, INC. | $21.10 | 2022 | |
| Tolmar, INC. | $19.92 | 2025 | Jatenzo |
| Ascensia Diabetes Care US INC. | $19.11 | 2023 | |
| Nabriva Therapeutics, Plc | $17.82 | 2020 | |
| Impel Pharmaceuticals INC. | $17.65 | 2022 | |
| Scilex Pharmaceuticals INC. | $17.60 | 2022 | |
| Vyera Pharmaceuticals, LLC | $17.46 | 2021 | |
| Boston Scientific Corporation | $17.36 | 2019 | |
| Scpharmaceuticals INC. | $16.49 | 2025 | |
| Vanda Pharmaceuticals INC. | $15.47 | 2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $14.68 | 2023 | Quviviq |
| Medtronic USA, INC. | $14.54 | 2019 | |
| Almatica Pharma LLC | $14.45 | 2021 | |
| Horizon Therapeutics Plc | $13.98 | 2021 | |
| Mission Pharmacal Company | $13.17 | 2019 | |
| Promius Pharma LLC | $12.66 | 2019 | |
| Bardy Diagnostics, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Kovacs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.